The sharp rise in Elizabeth Warren’s poll numbers in the Democratic presidential primary has coincided with a sharp decline in the shares of many biotech companies. But investors may be overly worried about Warren, and if that’s the case, there’s a buying opportunity among beaten-down biotech stocks – some of which are now so cheap that investors can get their research pipelines at a significant discount (or for free!). CLICK HERE.
